Table 4.
A549 | Region | Events | % Gated | % Total | X Mean | X Geo Mean | Y Mean | Y Geo Mean |
---|---|---|---|---|---|---|---|---|
Ctr | R1 | 9237 | 100.00 | 92.37 | 8.42 | 7.27 | 438.56 | 417.68 |
R2 | 17 | 0.18 | 0.17 | 154.21 | 120.98 | 618.82 | 588.02 | |
CDDP 70% IC50 | R1 | 5951 | 100.00 | 59.51 | 9.05 | 6.27 | 463.55 | 443.41 |
R2 | 26 | 0.44 | 0.26 | 156.55 | 64.74 | 418.65 | 404.21 | |
VPA 70% IC50 | R1 | 9626 | 100.00 | 96.26 | 15.00 | 8.78 | 469.60 | 428.63 |
R2 | 404 | 4.20 | 4.04 | 141.39 | 101.77 | 453.67 | 409.01 | |
VPA+CDDP 70% IC50 | R1 | 9553 | 100.00 | 95.53 | 29.80 | 12.92 | 591.59 | 557.49 |
R2 | 1260 | 13.19 | 12.60 | 155.83 | 127.96 | 532.78 | 502.44 | |
SAHA 70% IC50 | R1 | 8860 | 100.00 | 88.60 | 9.50 | 7.36 | 311.01 | 278.37 |
R2 | 76 | 0.86 | 0.76 | 88.89 | 64.58 | 336.67 | 300.38 | |
SAHA+CDDP 70% IC50 | R1 | 7551 | 100.00 | 75.51 | 15.15 | 9.80 | 531.33 | 504.17 |
R2 | 191 | 2.53 | 1.91 | 163.22 | 120.11 | 492.93 | 471.69 | |
CDDP 120% IC50 | R1 | 9723 | 100.00 | 97.23 | 13.80 | 10.38 | 557.91 | 537.33 |
R2 | 335 | 3.45 | 3.35 | 100.21 | 87.73 | 445.07 | 420.25 | |
VPA 120% IC50 | R1 | 9614 | 100.00 | 96.14 | 10.66 | 7.62 | 399.43 | 374.29 |
R2 | 119 | 1.24 | 1.19 | 191.94 | 153.40 | 363.56 | 334.57 | |
VPA+CDDP 120% IC50 | R1 | 9754 | 100.00 | 97.54 | 20.06 | 8.60 | 440.97 | 421.18 |
R2 | 2332 | 23.91 | 23.32 | 66.30 | 59.62 | 461.03 | 442.99 | |
SAHA 120% IC50 | R1 | 9585 | 100.00 | 95.85 | 9.24 | 7.97 | 484.04 | 458.75 |
R2 | 22 | 0.23 | 0.22 | 146.17 | 117.48 | 464.23 | 427.33 | |
SAHA+CDDP 120% IC50 | R1 | 9678 | 100.00 | 96.78 | 14.61 | 9.86 | 433.49 | 413.62 |
R2 | 1173 | 12.12 | 11.73 | 56.64 | 49.96 | 391.34 | 374.33 |
A549 lung cancer cell line was incubated with active agents alone or in mixture of them with doses 1.4 = 70% IC50 and 2.4 = 120% IC50 for 48 h. Data was analyzed by flow cytometry.